US-based OncoMed Pharmaceuticals has started dosing patients in the Phase Ia clinical trial of anti-TIGIT (OMP-313M32) to treat advanced or metastatic solid tumours.

OMP-313M32 is an immuno-oncology therapeutic candidate being developed to prevent immune system suppression, as well as induce anti-tumour activity.

The open-label Phase Ia trial will evaluate the safety and tolerability of increasing doses of anti-TIGIT administered as a monotherapy every two weeks in up to 30 patients at five clinical sites.

OncoMed clinical research and development senior vice-president Robert Stagg said: “In multiple preclinical studies of anti-TIGIT antibodies, we have observed immune activation and single-agent, as well as combination anti-tumour activity, including indications that an anti-TIGIT antibody induced a long-term immune memory response.

“The initiation of this Phase Ia anti-TIGIT study represents the first of our novel immuno-oncology therapeutics to enter clinical trials.

"The initiation of this Phase Ia anti-TIGIT study represents the first of our novel immuno-oncology therapeutics to enter clinical trials."

"We believe that by blocking TIGIT signalling, our anti-TIGIT antibody may enable T-cell activation and facilitate anti-tumour immune responses with the potential to impact tumour growth.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial's secondary objectives include anti-TIGIT's pharmacokinetics, immunogenicity and anti-tumour efficacy.

The pharmacodynamic and potential predictive biomarkers for changes in immune system activation will also be assessed.

Anti-TIGIT trial lead investigator Johanna Bendell said: “The immuno-suppressive receptor TIGIT is expressed in many different tumour types, giving us reason to believe that an anti-TIGIT antibody such as OncoMed’s OMP-313M32 has the potential for broad activity in cancer patients."

An expansion cohort will recruit patients with select tumour types, following the determination of a maximum-tolerated dose.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now